Advertisement

Journal of Clinical Immunology

, Volume 33, Issue 4, pp 748–758 | Cite as

Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency

  • Ivan J. Fuss
  • Julia Friend
  • Zhiqiong Yang
  • Jian Ping He
  • Lubna Hooda
  • James Boyer
  • Liqiang Xi
  • Mark Raffeld
  • David E. Kleiner
  • Theo Heller
  • Warren Strober
Original Research

Abstract

Purpose

Patients with Common Variable Immunodeficiency (CVID) are subject to the development of a liver disease syndrome known as nodular regenerative hyperplasia (NRH). The purpose of this study was to define the characteristics and course of this complication of CVID.

Methods

CVID patients were evaluated by retrospective and prospective clinical course review. Liver biopsy specimens were evaluated for evidence of NRH and studied via RT-PCR for cytokine analysis.

Results

NRH in our CVID patient population occurred in approximately 5 % of the 261 patients in our total CVID study group, initially presenting in most cases with an elevated alkaline phosphatase level. While in some patients the disease remained static, in a larger proportion a more severe disease developed characterized by portal hypertension, the latter leading to hypersplenism with neutropenia and thrombocytopenia and, in some cases, to ascites. In addition, a substantial proportion of patients either developed or presented initially with an autoimmune hepatitis-like (AIH-like) liver disease that resulted in severe liver dysfunction and, in most cases to death due to infections. The liver histologic findings in these AIH-like patients were characterized by underlying NRH pattern with superimposed interface hepatitis, lymphocytic infiltration and fibrosis. Immunologic studies of biopsies of NRH patients demonstrated the presence of infiltrating T cells producing IFN-γ, suggesting that the NRH is due to an autoimmune process.

Conclusion

Overall, these studies provide evidence that NRH may not be benign but, can be a severe and potentially fatal disease complication of CVID that merits close monitoring and intervention.

Keywords

CVID NRH autoimmune liver hypertension cytokine 

Notes

Acknowledgments

Lubna Hooda was funded in whole or in part by the Frederick National Laboratory under Contract No. HHSN261200800001E. The contents of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products or organizations imply endorsement by the US government.

Sources of funding

Funding is from the intramural program of the NIAID, NCI, National Institutes of Health. None of the authors has any financial relationships with industries that have an interest in the subject matter or materials discussed in the manuscript.

Supplementary material

10875_2013_9873_MOESM1_ESM.doc (30 kb)
ESM 1 (DOC 29.5 kb)
10875_2013_9873_MOESM2_ESM.doc (15 kb)
ESM 2 (DOC 15.0 kb)

References

  1. 1.
    Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Moillot G, Jaussaud R, et al. DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009;9:347–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Cunningham-Rundles C, Radigan L, Knight AK, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176:1978–87.PubMedGoogle Scholar
  5. 5.
    Salzer U, Grimbacher B. Common variable immunodeficiency: the power of co-stimulation. Semin Immunol. 2006;18:337–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Giovanetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodefiency. J Immunol. 2007;178:3932–43.Google Scholar
  7. 7.
    Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol. 2007;98:8–11.CrossRefGoogle Scholar
  8. 8.
    Knight A, Cunningham Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Mannon PJ, Fuss IJ, Friend J, Hornung R, Yang Z, Yi C, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;13:748–56.CrossRefGoogle Scholar
  10. 10.
    Malamut G, Verkarre V, Suarez F, Villard JF, Lascaux AS, Cosnes J, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenteropathy. 2010;105:2262–75.CrossRefGoogle Scholar
  11. 11.
    Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaus AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48:74–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol. 2008;153:331–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Wanless IR. Micronuodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44:7–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Lopatin U, Yao X, Williams RK, Blessing JJ, Dale JK, Wong D, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood. 2001;97:3161–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443–51.PubMedGoogle Scholar
  18. 18.
    Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American group for immunodeficiency) and ESID (European society for immunodeficiencies). Clin Immunol. 1999;93:190–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenic relationship. Am J Gastroenterol. 1996;91:879–84.PubMedGoogle Scholar
  20. 20.
    Ravindran J, Gillis D, Rowland R, Heddle R. Common variable immunodeficiency associated with nodular regenerative hyperplasia of the liver. Aust NZ J Med. 1995;25:741.CrossRefGoogle Scholar
  21. 21.
    Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol. 2009;133:198–207.PubMedCrossRefGoogle Scholar
  22. 22.
    Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology. 1997;26:343–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Ziol M, Poirel H, Koutchou GN, Boyer O, Mohand D, Mouthon L, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol. 2004;35:1241–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2013

Authors and Affiliations

  • Ivan J. Fuss
    • 1
    • 7
  • Julia Friend
    • 1
    • 8
  • Zhiqiong Yang
    • 1
  • Jian Ping He
    • 3
  • Lubna Hooda
    • 1
    • 2
  • James Boyer
    • 4
  • Liqiang Xi
    • 5
  • Mark Raffeld
    • 5
  • David E. Kleiner
    • 5
  • Theo Heller
    • 6
  • Warren Strober
    • 1
  1. 1.Mucosal Immunity Section, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  2. 2.Clinical Research Directorate/CMRP, SAIC-Frederick, Inc.Frederick National Laboratory for Cancer ResearchFrederickUSA
  3. 3.Mucosal Immunobiology Section, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  4. 4.Division of Digestive DiseasesYale UniversityBethesdaUSA
  5. 5.Laboratory of Pathology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  6. 6.Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA
  7. 7.Mucosal Immunity SectionLaboratory of Host DefensesBethesdaUSA
  8. 8.Urologic Oncology Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations